Last reviewed · How we verify
NCT06791460
Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer
Phase 2, PHASE3 trial testing Pegylated liposomal doxorubicin plus adebrelimab with mirabegron in Ovarian Cancer Recurrent in 296 participants. Currently enrolling.
14 February 2028
Quick facts
| Lead sponsor | Obstetrics & Gynecology Hospital of Fudan University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 296 |
| Start date | 18 March 2025 |
| Primary completion | 14 February 2028 |
| Estimated completion | 14 February 2030 |
| Sites | 1 location across China |
Drugs / interventions tested
- Pegylated liposomal doxorubicin plus adebrelimab with mirabegron — full drug profile →
- Pegylated liposomal doxorubicin plus adebrelimab — full drug profile →
Conditions studied
- Ovarian Cancer Recurrent — all drugs for Ovarian Cancer Recurrent →
Sponsor
Obstetrics & Gynecology Hospital of Fudan University
Who can join
Adults 18 to 75, female only, with Ovarian Cancer Recurrent. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if drug regimen pegylated liposomal doxorubicin and adebrelimab with or without mirabegron works to treat relapsed ovarian cancer in adults. It will also learn about the safety of drug regimen pegylated liposomal doxorubicin and adebrelimab with or without mirabegron. The main questions it aims to answer are: Does drug pegylated liposomal doxorubicin and adebrelimab with or without mirabegron reduce tumor volume? What medical problems do participants have when taking drug pegylated liposomal doxorubicin and adebrelimab with or without mirabegron? Researchers will compare drug regimen pegylated liposomal doxorubicin and adebrelimab with mirabegron to a drug regimen pegylated liposomal doxorubicin and adebrelimab without mirabegron to see which drug regimen works better to treat relapsed ovarian cancer. Participants will: Take drug pegylated liposomal doxorubicin and adebrelimab every 21 days with or without everyday mirabegron Visit the clinic once every 2 months for checkups and tests Keep a diary of their symptoms
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06791460
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer Recurrent
Currently open trials in the same condition.
- NCT07030907 — A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer · Phase 1 · recruiting
- NCT06843447 — A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) · Phase 1, PHASE2 · recruiting
- NCT06660511 — Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Tr · EARLY_PHASE1 · recruiting
- NCT05990192 — SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy · Phase 2 · recruiting
- NCT06781151 — A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB · recruiting
Other Obstetrics & Gynecology Hospital of Fudan University trials
Trials by the same sponsor.
- NCT07523308 — Efficacy and Safety of Intra-operative Dual Laparoscopy and Neo-rectoscopy vs Conventional Laparoscopy for Bowel Endomet · NA · not yet recruiting
- NCT07318701 — Multi-agent LLMs for Decision Support in Cervical Cancer During Pregnancy · NA · not yet recruiting
- NCT07130240 — Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 a · Phase 2 · recruiting
- NCT07202728 — A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01) · recruiting
- NCT06904131 — A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06791460 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Obstetrics & Gynecology Hospital of Fudan University
- Last refreshed: 18 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06791460.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing